No­var­tis sets the tone for the ra­dio­phar­ma push with a prized ac­qui­si­tion win­ning break­through ther­a­py des­ig­na­tion

The crown jew­el of a multi­bil­lion-dol­lar No­var­tis ac­qui­si­tion has won a new en­dorse­ment from the FDA, and it’s a pro­gram at the fore­front of the in­dus­try’s ra­dio­phar­ma push.

Reg­u­la­tors grant­ed Lu-PS­MA-617 break­through ther­a­py des­ig­na­tion Wednes­day, No­var­tis an­nounced, rough­ly three months af­ter the can­di­date read out pos­i­tive Phase III re­sults in metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer. The move marks not on­ly a win for No­var­tis but for the up-and-com­ing ra­dio­phar­ma­ceu­ti­cals field, which has at­tract­ed heavy in­ter­est in the last cou­ple years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.